Total medical devices industry M&A deals worth $2.38bn were announced in Europe in Q1 2021, led by Thermo Fisher Scientific’s $880.85m asset transaction with Novasep Holding, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

The value marked an increase of 133.3% over the previous quarter and a rise of 362.6% when compared with the last four-quarter average of $514.52m.

Europe held a 7.75% share of the global medical devices industry M&A deal value that totalled $30.7bn in Q1 2021. With a 3.75% share and deals worth $1.15bn, Belgium was the top country in Europe’s M&A deal value across medical devices industry.

In terms of deal activity, Europe recorded 36 deals during Q1 2021, marking a decrease of 5.26% over the previous quarter and a rise of 10.77% over the last four-quarter average. Germany recorded ten deals during the quarter.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Europe medical devices industry M&A deals in Q1 2021: Top deals

The top five medical devices industry M&A deals accounted for 90.5% of the overall value during Q1 2021.

The combined value of the top five M&A deals stood at $2.15bn, against the overall value of $2.38bn recorded for the quarter.

The top five medical devices industry deals of Q1 2021 tracked by GlobalData were:

1) Thermo Fisher Scientific’s $880.85m asset transaction with Novasep Holding

2) The $591m acquisition of Oxford Immunotec by PerkinElmer

3) Savaria’s $409.7m acquisition of Handicare Group

4) The $159m acquisition of Diagenode by Hologic

5) Sino Biopharmaceutical’s acquisition of 60% stake in Softhale for $110m.